Bibliography
- De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007;6:1001-18
- Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J Antimicrob Chemother 2003;51:213-7
- Miller M, Witmer M, Stillmock K, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor [abstract no. THAA0302]. In AIDS 2006 – XVI International AIDS Conference, Toronto;2006: Oral abstract session
- Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50
- Merck & Co., Inc. HIV integrase inhibitors. WO199962513; 1999
- Merck & Co., Inc. HIV integrase inhibitors. WO199962897; 1999
- Merck & Co., Inc. HIV integrase inhibitors. WO199962520; 1999
- Instituto Di Ricerche Di Biologica Moleculare P Angeletti SPA. N-Substituted hydroxypyrimidinone inhibitors of HIV integrase. WO2003035077; 2003
- Merck & Co., Inc. Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds. US20050090668; 2005
- Merck & Co., Inc. and Instituto Di Ricerche Di Biologica Moleculare P Angeletti SPA.: Potassium salt of an HIV integrase inhibitor. WO2006060712; 2006
- Instituto Di Ricerche Di Biologica Moleculare P Angeletti SPA. Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors. WO2004058756; 2004
- Instituto Di Ricerche Di Biologica Moleculare P Angeletti SPA. Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors. WO2004058757; 2004
- Merck & Co., Inc. and Banyu Pharmaceutical Co., Ltd. Process for preparing hexahydropyrimido[1,2-A]azepine-2-carboxylates and related compounds. WO2005061501; 2005
- Merck & Co., Inc. Process for asymmetric synthesis of hexahydropyrimido[1,2-A]azepine-2-carboxamides and related compounds. WO2006060225; 2006
- Instituto Di Ricerche Di Biologica Moleculare P Angeletti SPA. HIV integrase inhibitors. WO2006103399; 2006
- Merck & Co., Inc. HIV integrase inhibitors. WO2005092099; 2005
- Instituto Di Ricerche Di Biologica Moleculare P Angeletti SPA. HIV integrase inhibitors. WO2005087766; 2005
- Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors. WO2004024078; 2004
- Merck & Co., Inc. HIV integrase inhibitors. WO2005087767; 2005
- Merck & Co., Inc. HIV integrase inhibitors. WO2005087768; 2005
- Merck & Co., Inc. Crystalline sodium salt of an HIV integrase inhibitor. WO2006107478; 2006
- Merck & Co., Inc. HIV integrase inhibitors. WO200611831; 2006
- Merck & Co., Inc. HIV integrase inhibitors. WO2008048538; 2008
- Merck & Co., Inc. HIV integrase inhibitors. WO2005086700; 2005
- Merck & Co., Inc. 8-Hydroxy-1-oxo-tetrahydropyrrolopyrazone compounds useful as HIV integrase inhibitors. WO2004047725; 2004
- Merck & Co., Inc. HIV integrase inhibitors. WO2005120516; 2005
- Merck & Co., Inc. HIV integrase inhibitors. WO2007050510; 2007
- Merck & Co., Inc. Hydroxy pyridopyrrolopyrazone dione compounds useful as HIV integrase inhibitors. WO2005041664; 2005
- Merck & Co., Inc. HIV integrase inhibitors. WO2005110414; 2005
- Merck & Co., Inc. HIV integrase inhibitors. WO2005110415; 2005
- Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors WO200230930; 2002
- Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-100
- Tabata H, Akiba K, Lee S, et al. Atropisomeric properties of the dibenzo[b,d]azepin-6-one nucleus. Org Lett 2008;10:4871-4
- Prelog V, Helmchen G. Basic principles of the CIP-system and proposals for a revision. Angew Chem Int Ed Engl 1982;21:567-83
- Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007;12:563-70